Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Author(s) -
Malin Hultcrantz,
Sigurður Y. Kristinsson,
Therése Andersson,
Ola Landgren,
Sandra Eloranta,
Åsa Rangert Derolf,
Paul W. Dickman,
Magnus Björkholm
Publication year - 2012
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2012.42.1925
Subject(s) - medicine , myelofibrosis , polycythemia vera , relative survival , essential thrombocythemia , life expectancy , population , survival rate , cancer , gastroenterology , cancer registry , bone marrow , environmental health
Reported survival in patients with myeloproliferative neoplasms (MPNs) shows great variation. Patients with primary myelofibrosis (PMF) have substantially reduced life expectancy, whereas patients with polycythemia vera (PV) and essential thrombocythemia (ET) have moderately reduced survival in most, but not all, studies. We conducted a large population-based study to establish patterns of survival in more than 9,000 patients with MPNs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom